NEW DELHI: The Union Ministry of Health said on Tuesday that India was doing relatively well in the fight against the Covid-19 pandemic and was talking about the way forward. Vaccinations.
Union Health Minister Rajesh Bhushan said it is 29,000 cold chain points, 240 walk-in refrigerators, 70 walk-in freezers, 45,000 ice-lined refrigerators and 41,000 deep Freezers and 300 solar Refrigerators is used for this purpose. He added that all of these devices have already reached different states.
However, he also cautioned about the adverse effects, saying that such adverse effects mainly occur in children and pregnant women after vaccination.
Bhushan also referred international cases to clarify its point of view: India cannot deny the likelihood of adverse events when vaccination against Covid-19 begins. “In the countries where vaccination has started, especially the UK, adverse events occurred on the first day,” he said.
Bhushan urged states and UTs to prepare for such scenarios. He said the number of cases per million people in this country remains among the lowest in the world. While the global average is 9,000, the number of cases in India is 7,178 per million people.
Meanwhile, NITI Aayog Member (Health) VK Paul admitted to controlling Delhi’s spike in Covid and congratulated the government on it. But he strictly warned not to take this lightly, adding that the curve can go wrong too.
“There are some states where we still have concerns,” he said, calling on the government and citizens of Uttarakhand, Nagaland and Himachal Pradesh to “make every effort” to bring the current situation under control.
“This week, the Drugs Controller General of India approved clinical trials with another vaccine candidate from India,” he said. The Genoa company developed a vaccine with the help of the centre’s biotechnology department.
The technology used in it is similar to Pfizer. However, unlike Pfizer, it can be kept in a regular refrigerator under normal cold chain conditions, Paul added. He claimed that six vaccines are currently undergoing clinical trials in India.